Where Biogen Stands With Analysts
Where Biogen Stands With Analysts
Biogen在分析师中的立场
20 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives.
20位分析师分享了他们最近三个月对Biogen（纳斯达克股票代码：BIIB）的评估，表达了看涨和看跌的观点。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的评级，展示了过去30天情绪的演变，并将其与前几个月进行了比较。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $294.95, a high estimate of $364.00, and a low estimate of $215.00. This current average represents a 4.71% decrease from the previous average price target of $309.54.
分析师通过对12个月目标股价的评估提供了更深入的见解，显示平均目标价为294.95美元，最高估计为364.00美元，低估值为215.00美元。目前的平均价格比之前的平均目标股价309.54美元下降了4.71％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析师评级：全面细分
An in-depth analysis of recent analyst actions...
对分析师近期行为...
登录免费看全文
登录/注册